
Women warned against using ‘skinny jabs' whilst pregnant
The UK Medicines and Healthcare products Regulatory Agency (MHRA) also said women should not take weight loss drugs if they are breastfeeding or trying to get pregnant, because there isn't enough safety data to know whether the medicine could affect their baby.
'Anyone who gets pregnant while using them should speak to their healthcare professional and stop the medicine as soon as possible,' the agency said.
Meanwhile, all women taking the jabs should ensure they are using a form of contraception that works, the MHRA said.
One of the drugs, Mounjaro, may make birth control pills less effective, so the agency says women taking the jab should also use a non-oral form of contraception, like an implant or intrauterine device (IUD).
'Obesity reduces fertility in women. So, women with obesity taking GLP-1 drugs are more likely to get pregnant than before they lost weight,' Dr Channa Jayasena, a reproductive endocrinology researcher at Imperial College London, said in a statement.
'Women are advised to do all they can to prevent pregnancy while taking [these] drugs,' Jayasena added.
In the UK, women already receive these warnings when they get their prescriptions for the blockbuster jabs, which include Ozempic, Wegovy, Saxenda, and Victoza as well as Mounjaro.
The drugs, known as GLP-1 receptor agonists, work by mimicking hormones that help regulate appetites and make people feel full for longer. They have been approved to treat type 2 diabetes and obesity.
But the MHRA issued the reminder Thursday due to concerns that the drugs' growing popularity means women are buying them illegally online or at beauty salons, without seeing a doctor.
'Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments,' Dr Alison Cave, MHRA's chief safety officer, said in a statement.
'They are not a quick fix to lose weight and have not been assessed to be safe when used in this way,' she added.
Between 'unprecedented' cocaine availability, counterfeit painkillers that contain deadly synthetic opioids, and evasive trafficking networks, Europe's drug problems are more complex than ever.
That's according to the European Union Drugs Agency (EUDA), which says illegal drugs are taking their toll across the entire bloc due to addiction, increases in gang violence, and burdened health systems.
'Today we face a fast-changing situation everywhere in Europe,' Alexis Goosdeel, the agency's executive director, told Euronews.
An estimated 7,500 people died from drug overdoses in 2023, up from about 7,100 the year before, the analysis found.
Most overdose deaths involved opioids, but the risks are changing as more people turn to synthetic drugs and use multiple substances.
EU officials called for more proactive efforts to prevent and treat addiction, rather than simply monitoring drug use, as well as increased police efforts to dismantle criminal networks that traffic drugs.
Here's what the latest data shows on illegal drug trends across the EU, Norway, and Turkey – and what health authorities are most worried about going forward.
Europe's opioid market is changing, with other substances emerging alongside long-term heroin risks.
After the Taliban took over in Afghanistan in 2021 and banned opium production the following year, European officials warned that heroin could become harder to find, prompting people to turn to dangerous fentanyl derivatives or synthetic opioids.
In 2023, authorities dismantled 14 heroin production sites in Europe, mostly in the Netherlands.
One type of synthetic opioid, called nitazenes, is already causing problems in places like Denmark and the Netherlands, where health authorities have warned that people could be buying counterfeit painkillers that actually contain nitazenes.
In 2023, the number of nitazene powders detected in Europe tripled. The drugs are so potent that even a small dose can be life-threatening.
Germany, France, Sweden, and Norway have reported clusters of overdoses linked to nitazenes, the EUDA said, while the drugs appear to be responsible for a 'significant share' of overdose deaths in Estonia and Latvia.
'What we see already is people who are buying on the internet molecules, believing that they are medicines while in fact they contain other substances,' Goosdeel said.
In the past year, about 4.6 million European adults have used cocaine, making it the bloc's most commonly used illegal stimulant.
It's also becoming more popular. In 2023, EU member states seized 419 tonnes of cocaine – marking the seventh year in a row of record seizures.
The biggest busts were in Belgium (123 tonnes), Spain (118 tonnes), and the Netherlands (59 tonnes), which are key entry points for cocaine trafficked into Europe from elsewhere in the world.
Last year, Spain seized 13 tonnes of cocaine, which were hidden in bananas from Ecuador – its largest ever haul from a single bust.
Cocaine is also developed in the EU, with authorities dismantling 34 production sites in 2023.
The competitive market is driving an uptick in cocaine-related crime and gang violence, the report found.
The EUDA expects there to be a surge of people seeking addiction treatment in the coming years, given that there tends to be a lag of about 13 years between someone's first time trying cocaine and their first time seeking treatment.
'We need to build the capacity to be prepared for treatment,' Goosdeel said, because at the moment, 'we are not ready'.
An estimated 8.4 per cent of adults – 24 million people – used cannabis in the past year, making it Europe's most commonly used illegal drug, the report found.
Cannabis seizures rose slightly in 2023 after falling the year before, the report found. The market is worth at least €12.1 billion, and is run by organised criminal groups that cultivate, traffic, and sell the drug across Europe.
Cannabis may be common, but it isn't without its health risks. It can cause or worsen chronic respiratory issues and psychotic symptoms, with long-term, regular users at higher risk.
Meanwhile, a class of drugs known as synthetic cannabinoids are a growing concern, the EUDA said.
These highly potent drugs may be added to edibles or other cannabis products without people's knowledge, raising the risk of poisoning or other health problems.
Last year, European countries detected 20 new cannabinoids, representing more than 40 per cent of the new substances identified by the EU's early warning system.
The possible health consequences of cannabinoids are 'poorly understood,' the report said. Still, they may be tied to fatal poisonings or other problems because they have such a high concentration of THC, the active ingredient in cannabis that makes people feel high.
'So yes, there is a danger,' Goosdeel said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Euronews
5 days ago
- Euronews
Eli Lilly hikes UK price of blockbuster weight loss drug Mounjaro
Drugmaker Eli Lilly said it will raise the price of its blockbuster weight loss drug by up to 170 per cent for customers in the United Kingdom. The US pharmaceutical giant confirmed to Euronews Health that effective September 1, the highest dose of Mounjaro will cost £330 for a month's supply, up from £122 currently. The new price is the list price, or what private providers will pay for the drug. Clinics are expected to raise their prices for patients as a result. The price hike is not expected to affect access for patients who receive Mounjaro through the National Health Service (NHS), a spokesperson for NHS England said. 'The approved list price increase will not affect NHS commissioning of [Mounjaro] in England for eligible people living with obesity, based on clinical priority, or as a treatment for type 2 diabetes,' the spokesperson told Euronews Health. The NHS England spokesperson said patients who get the drug through private doctors should contact their providers. A Lilly spokesperson said the company will work with private doctors to "maintain patient access'. Mounjaro is used to treat obesity, type 2 diabetes, and weight-related health problems in both the UK and the European Union. Rival weight loss jabs Ozempic and Wegovy, made by Danish drugmaker Novo Nordisk, are also available. A Lilly spokesperson said the increase aims to bring Mounjaro's UK price closer to what is paid in other European countries. 'At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS availability,' the spokesperson said. 'With changes in the environment and new clinical evidence supporting the value of Mounjaro, we are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation'. The move comes as US President Donald Trump puts pressure on pharmaceutical companies to lower drug costs for Americans to a level that matches the lowest price offered in other wealthy countries. In May, Trump complained that a 'friend' of his paid significantly less for 'the fat shot' in the UK than in the United States. He later accused European countries of 'freeloading,' saying Americans pay higher prices to cover the cost of new drug development while other wealthy countries benefit. Since then, some drug companies have signaled they will attempt to align prices paid in the US and other countries. The Lilly spokesperson said the Mounjaro price increase will 'address pricing inconsistencies compared to other developed countries, including in Europe'.


Euronews
08-08-2025
- Euronews
Portugal limits weight loss drug prescriptions to prevent misuse
Portugal is restricting doctors' ability to prescribe blockbuster weight loss drugs and monitors that track blood sugar levels, over concerns that they are being misused. As of Friday, only doctors from four medical specialties will be able to prescribe glucose sensors and drugs like Ozempic, Wegovy, and Mounjaro, which are known as glucagon-like peptide-1 (GLP-1) receptor agonists. Used to treat type 2 diabetes and obesity, the medicines help people lose weight by mimicking a hormone that makes them feel full for longer. The injectable drugs are in high demand, though, which has led to availability problems on the market. This is the case with Ozempic from the Danish laboratory Novo Nordisk. Ozempic is only approved in Portugal to treat type 2 diabetes, but it is highly sought after for weight loss. Mounjaro (Eli Lilly) and Wegovy (Novo Nordisk) are approved for both diabetes and obesity. In the first four months of 2025, Portuguese consumers spent around €21 million on these medicines. Now, only doctors from the approved specialties – endocrinology and nutrition, internal medicine, paediatrics, and general and family medicine – will be able to prescribe them. Glucose sensors have also been in high demand by non-diabetics, causing a shortage of these monitors in pharmacies. According to the Público newspaper, they are prescribed by doctors who do not work with diabetes patients, and are highly sought after by dieters, athletes, influencers, and even for use on animals. Portugal's Ministry of Health posted the regulation in April, warning of "recent reports of improper access to and use of these same technologies, which have jeopardised their availability to those who actually need them". "This decree aims to regulate and correct these distortions, promoting effective and adequate access to these essential health tools," the ministry said. The president of the Portuguese Society of Diabetology (SPD) praised the measure, but says it is late and may not solve the problem of difficult access to these medicines. "We're waiting to see if [the measure] will simplify or facilitate access," said João Raposo, speaking to the Lusa news agency. "I personally have some doubts, because I have the idea that the number of prescriptions outside of these specialties is not significant," Raposo added. He said that diabetics and doctors are not opposed to these drugs being used to treat obesity. But there are "anomalous prescriptions and a lack of monitoring of these people," he said. "Health cannot be subject to the laws of the market, because we know that it is very tempting for this population, which is desperately looking for solutions. The market has worked and we shouldn't have let it happen," he added. GLP-1 agonist medicines are reimbursed by the Portuguese state at 90 per cent. Sensor reimbursement can be as high as 85 per cent. In addition to prescriptions, there is also a high demand for these medicines on the black market, which can lead to problems with counterfeiting.


Euronews
07-08-2025
- Euronews
Experimental pill helped with weight loss in Eli Lilly trial
An experimental once-daily pill to treat obesity can help people lose a significant amount of weight, according to new data from drugmaker Eli Lilly. The medicine, called orforglipron, belongs to a class of blockbuster weight loss drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists, which work by mimicking a hormone that makes people feel full for longer. Most GLP-1 drugs – like Ozempic, Wegovy, and Mounjaro – must be injected, so pharmaceutical companies have been racing to find alternatives. Lilly's pill may be the first to get there. The company plans to ask regulators to approve orforglipron by the end of the year, and said it is ready to begin rolling out the medicine globally. If it's approved, the pill could offer 'a convenient alternative to injectable treatments,' Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health, said in a statement. The clinical trial included more than 3,100 adults who were overweight or obese and had a weight-related health problem other than patients with diabetes. After 72 weeks, the participants taking 36mg of orforglipron per day lost an average of 12.4 kilograms, or 12.4 per cent of their body weight. Notably, that is not as much as people on other anti-obesity medicines. In one study, for example, people taking Novo Nordisk's Wegovy lost 13.2 per cent of their weight and those on Lilly's Zepbound lost 20.2 per cent over 72 weeks. But the ability to take orforglipron as a daily pill rather than an injectable jab may drive up demand. In the study, other cardiovascular risk factors also improved for patients, including their cholesterol, triglycerides, and blood pressure. Orforglipron's side effects were mostly gastrointestinal, for example, constipation, diarrhoea, and vomiting, similar to other weight loss drugs. Simon Cork, a senior lecturer in physiology at Anglia Ruskin University in the United Kingdom, said the findings are a 'positive step forward in the development of these class of drugs'. Eli Lilly reported the data in a news release, and it has not yet been published in a peer-reviewed journal. The company said it will release more details next month at the European Association for the Study of Diabetes (EASD). "Obesity is one of the most pressing global health challenges of our time, driving global chronic disease burden and impacting more than one billion people worldwide," Custer said.